Company: BDRX
Filing Date: 2025-09-12
Form Type: 424B3
Source: 0001214659-25-013681
Chunk: 18

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-12
Form: 424B3
Chunk 18
---
 |     |                            32 |     |                            86 |
| Other interest                                        |     |                             3 |     |                             2 |
| Gain on equity settled derivative financial liability |     |                           145 |     |                           751 |
| Total finance income                                  |     |                           180 |     |                           839 |

The gain on the
equity settled derivative financial liability in 1H25 and 1H24 arose as a result of the fall in the Biodexa share price.

|                                            |     |                    Six months 
                         ended 
 June 30, 2025 unaudited £’000 |     |                    Six months 
                         ended 
 June 30, 2024 unaudited £’000 |
|:-------------------------------------------|:----|------------------------------:|:----|------------------------------:|
| Finance expense                            |     |                               |     |                               |
| Interest expense on lease liabilities      |     |                             6 |     |                            11 |
| Interest expense on deferred consideration |     |                            86 |     |                            38 |
| Other loans                                |     |                            43 |     |                             - |
| Total finance expense                      |     |                           135 |     |                            49 |

| 18 |

| 4. | Loss per share |

Basic loss per
share amounts are calculated by dividing the net loss for the period from continuing operations, attributable to ordinary equity holders
of the parent company, by the weighted average number of ordinary shares outstanding during the period. As the Group made a loss for the
period the diluted loss per share is equal to the basic loss per share.

| Schedule of loss per share                                   |     | Six months ended June 30, 2025 unaudited £’000 |   |     | Six months ended June 30, 2024 unaudited £’000 |   |
|:-------------------------------------------------------------|:----|-----------------------------------------------:|:--|:----|-----------------------------------------------:|:--|
| Numerator                                                    |     |                                                |   |     |                                                |   |
| Loss used in basic EPS and diluted EPS:                      |     |                                         (3,806 | ) |     |                                         (3,308 | ) |
| Denominator                                                  |     |                                                |   |     |                                                |   |
| Weighted average number of ordinary shares used in basic EPS |     |                                 25,267,266,823 |   |     |                                  3